Searched for
JANSSEN SCIENCES
Biocon settles with Janssen to commercialise biosimilar products in Europe, Canada, JapanBiocon Biologics has entered into a settlement and licence agreement with Janssen Biotech Inc, Janssen Sciences Ireland, and Johnson & John...- GSK India appoints Bhushan Akshikar as managing directorAkshikar with over 26 years experience within the pharmaceutical industry, joined GSK India in September 2011 to lead the specialty and com...
- USIBC appoints four new members to its India Advisory CouncilArundhati Bhattacharya, Chief Executive Officer and Chairperson, Salesforce India who has assumed the role of IAC Chair said the council pl...
- How Delta, Kappa variants of Covid evade immune systemthe Delta, Kappa, and Delta Plus variants reduce virus neutralising potency from vaccine-induced antibodies.
- Strides gets USFDA nod for generic Oxybutynin Chloride tabletsCompany's step-down wholly owned subsidiary Strides Pharma Global Pte Ltd, Singapore, has received approval for Oxybutynin Chloride Tablets...
- New Zealand secures two new COVID-19 vaccines, enough for every citizen: PMThe new agreements secure access to 7.6 million doses from AstraZeneca -- enough for 3.8 million people, and 10.72 million doses from Novav...
- Illegal cancer drugs from Bangladesh flood local marketIllegal import of drugs from Bangladesh and other neighbouring countries have further added to the woes of pharmaceutical companies. Expert...
- India's dependency on charitable program for MDR TB drugs not helping, doctors sayIndia's dependency on charity from global drug makers is making it hard for patients to access new antibiotic drugs such as bedaquiline and...
- Johnson & Johnson arm halts R&D on Hepatitis C drugInstead, the company will focus on a cure for chronic hepatitis B, an inflammation of the liver caused by a different virus.
- India may be first to go for simplified TB treatment plan"TB remains a significant challenge in India, killing approximately half a million-people in 2015 alone," said Anil Koul director, CSIR-IMT...
- Merck merges pharma, consumer health units; aims to ramp up businessesGoing against the grain: With the unique hybrid model for India, co aims at building scale & ramping up businesses.
- Reliance Life gains global rights for copies of InfliximabFor Infliximab, Reliance Life Sciences had completed process development, manufacturing, clinical trials in India and obtained marketing ap...
- Reliance Life Sciences ends deal with Epirus for Remicade copiesJanssen’s Remicade is the third biggest pharmaceutical brand globally with sales exceeding $8 billion last year.
- Boehringer Igelheim aims for top slot with anti-diabetes drug launchWith Jardiance, BI has the advantage of significantly reducing cardiovascular risks associated with most patients with diabetes.
- Scientist working on flu vaccine that lasts a lifetimeAs New Scientist explains, the flu virus carries big, globular "decoy" proteins on its surface to grab our immune system's attention.
- Faster way to create insulin-producing cells for diabeticsResearchers from the University of British Columbia developed the method which turns stem cells into insulin-producing cells in about six w...
- Jubilant Biosys expands drug discovery alliance with JanssenJubilant Biosys will carry out research services and deliver preclinical candidates to Janssen for potential development and commercialisat...
- Now, Indian pharma companies like Jubilant Group, TCG Life Sciences and Piramal Life Sciences venture to share new drug R&D risksIndian firms need handholding, but there have been times when they were left on their own after being assigned a project.
- Jubilant soars on drug discovery pact with Belgian firmPharma firm Jubilant Life Sciences soared over 11% after its US-based arm inked drug discovery pact with Belgium-based Janssen Pharmaceutic...
- 'Indian bio-pharma R&D spending could grow to $25 bn by 2025'India's bio-pharma sector may see a surge in R&D spending to about $25 billion in the next 15 years, according to a Boston Consulting Group...
Load More
